Corvus Pharmaceuticals (CRVS) Assets Average (2016 - 2026)

Corvus Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $162.2 million for Q1 2026.

• In Q1 2026, Assets Average rose 152.69% year-over-year to $162.2 million; the TTM figure through Mar 2026 stood at $162.2 million (up 152.69% YoY), while the FY2025 annual figure was $70.0 million, up 22.34% from the prior year.
• Assets Average was $162.2 million for Q1 2026 at Corvus Pharmaceuticals, up from $75.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $162.2 million in Q1 2026 to a low of $42.8 million in Q1 2024.
• Historically, Assets Average has averaged $74.7 million across 5 years, with a median of $64.2 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Assets Average plunged 40.03% in 2023, then soared 152.69% in 2026.
• A 5-year view of Assets Average shows it stood at $74.3 million in 2022, then slumped by 34.39% to $48.7 million in 2023, then surged by 31.0% to $63.9 million in 2024, then increased by 18.69% to $75.8 million in 2025, then surged by 113.94% to $162.2 million in 2026.
• The last three Assets Average figures came in at $162.2 million (Q1 2026), $75.8 million (Q4 2025), and $85.0 million (Q3 2025), per Business Quant data.